// App-Quantinova.ai

2515 : Glyco-optimized trastuzumab-GEX, a novel anti-HER2 monoclonal antibody with ADCC activity: A phase I clinical study in patients with HER2-positive tumors.

Researchers

Presenter

  • Hellmut Samonigg

Principal Investigators

  • Sara De Dosso

  • Bruno Dietrich

  • Kelvin Eckert

  • Hans Baumeister

  • Marc Oliver Salzberg

  • Steffen Goletz

  • Antonella Perotti

  • Walter Fiedler

  • Guenther Gastl

Medical Centers

  • Istituto Nazionale Tumori, Milano, Italy

  • Hubertus-Wald University Cancer Center, Hamburg, GermanyApeiron Biologics AG, Vienna, AustriaGlycotope GmbH, Berlin, Germany

  • Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University (IMU), Innsbruck, Innsbruck, Austria

  • Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

  • Division of Clinical Oncology, Department of Internal Medicine, Medical University Graz, Graz, Austria

Locations

  • Germany

  • Switzerland

  • Italy

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab

  • Trastuzumab glyco-optimised

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01409343

Sponsors

  • APEIRON Biologics AG

  • Glycotope GmbH

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved